Please login to the form below
patritumab
This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.
Daiichi gets breakthrough status for pre-NDA leukaemia drug
of HER3 inhibitor patritumab in combination with Roche’s EGFR drug Tarceva (erlotinib) in the same indication on disappointing efficacy data. ... Patritumab is still in mid-stage testing for head and neck cancer.
Latest news
-
Daiichi pulls study of patritumab in lung cancer
Daiichi Sankyo has halted a late-stage trial of its HER3 inhibitor patritumab after seeing no evidence of efficacy at an interim analysis. ... This particular result does not directly affect the science of patritumab in other settings," said Yver.
-
Daiichi Sankyo to shut down German antibody unit U3
cancer. . U3 Pharma's lead candidate patritumab (U3-1287), an anti-HER3 antibody in clinical trials for non-small cell lung cancer (NSCLC), breast cancer and head and neck cancer, was
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Novartis chooses internal replacement for US pharma president role
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- A uniquely English genomic medicine service
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- AZ claims first-in-class win for Farxiga in heart failure
- UK no longer measles-free as vaccination rates fall dramatically
- Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
- Blended Intelligence
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
Quick links
Infographics
